Skip to contentE
Editas Medicine, Inc.
E
EDITEditas Medicine, Inc. Q2 2021 · 10-Q
Revenue$379.00K$379.00K−96.5% vs Q2 2020 Net Income-$55.26M-$55.26MN/M vs Q2 2020 EPS Diluted-$0.81-$0.81N/M vs Q2 2020 Operating Income-$55,401,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Editas Medicine, Inc. · CIK 1650664 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$41,661,000N/M Margins · derivedOperating margin-14617.7%−14326.1 pt vs Q2 2020
Net margin-14579.4%−14360.1 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 5, 2021 · 36 d after period end